Prosecution Insights
Last updated: November 20, 2026
Application No. 19/213,407

Microbial Surfactants to Prevent and/or Remove Asphaltene Deposits

Non-Final OA §112
Filed
May 20, 2025
Priority
Apr 16, 2020 — provisional 63/010,910 +2 more
Examiner
RODD, CHRISTOPHER M
Art Unit
1766
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Locus Solutions IPCO LLC
OA Round
1 (Non-Final)
72%
Grant Probability
Favorable
1-2
OA Rounds
11m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
593 granted / 818 resolved
+7.5% vs TC avg
Moderate +12% lift
Without
With
+11.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
29 currently pending
Career history
840
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
43.2%
+3.2% vs TC avg
§102
18.3%
-21.7% vs TC avg
§112
25.4%
-14.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 818 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 3, 4, 8 and 9, 16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 3 depends on Claim 2 which is now canceled. Therefore, it is indefinite as to the claim dependency of Claim 3. Claim 4 contains 2 periods (an extra period between the claim number and claim identifier) rendering it indefinite as it if the claim actually only has 1 period as required. Claim 4 additionally recites “a lactonic sophorolipid” and depends from Claim 1 which has a specific lactonic sophorolipid. Therefore it is indefinite as to the sophorolipid required by the claim: the specific lactonic sophorolipid of Claim 1 or another lactonic sophorolipid which does not necessary have to be the lactonic sophorolipid of Claim 1. Claims 8 and 9 are method claims with recite a “use” with an active step in accomplishing this use. Therefore, they are improper use claims as it is indefinite as to what is required to accomplish the uses of Claim 8 and 9. Claim 16 recites hexanolmethanol which is not a recognized compound and the as-filed specification does not address what this compound is (See page 14 lines 20-21 of the as-filed specification). Therefore, the scope of compound recited by hexanolmethanol is not clear and indefinite. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 3 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 3 is considered as a dependent of Claim 1 (See §112 above), recites three different specific R3 all of which are C15 R3 according to both the formula of Claim 3 and the formula of Claim 1 while Claim 1 recites R3 is C18. Therefore, Claim 3 does not contain all the limitation from the claim which is reasonably is suggested to depend from. Note the carboxylic acid group is not part of the R3 formula in either case, therefore, that carbon does not count. Further, Claim 3 also recites R1 and R2 as hydrogen or acetyl groups (C=O-Me) and Claim 1 from which Claim 3 is reasonably suggested to depend recites the same R1 and R2 as only hydrogens. Therefore, Claim 3 does not contain all the limitations from the claim it is reasonably suggested to depend from. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter Claims 1, 6-7, 10-15 and 17-22 are allowed. Claims 3, 4, 8, 9, 16 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. The closest prior art is Armstrong (U.S. 20150300139) which teaches linear sophorolipids according to the claimed formula but for only teaching the cycloaliphatic rings have hydrogens for the non-functionalized portions of the rings while the instant claims require methyl groups. (See circled area as an example comparison) R3 according to both Armstrong and the claimed invention may be C18 in a range taught by Armstrong in ¶[0012]. PNG media_image1.png 272 342 media_image1.png Greyscale PNG media_image2.png 252 240 media_image2.png Greyscale This group may be a hydrogen or methyl group (R4) in the as-filed specification. (See page 13 lines 1-5 as-filed specification) and is consistent with common chemical notation for methyl groups on hydrocarbons (see ¶[0031] of Armstrong). Therefore, to practice the invention of Armstrong by making a methylated sophorolipid as claimed along with only choosing a C18 group for R3 would require the use of hindsight. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER M RODD whose telephone number is (571)270-1299. The examiner can normally be reached 7 am - 3:30 pm (Pacific). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Randy Gulakowski can be reached on (571) 272-1302. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Christopher M Rodd/ Primary Examiner, Art Unit 1766
Read full office action

Prosecution Timeline

May 20, 2025
Application Filed
Aug 05, 2026
Response after Non-Final Action
Nov 02, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790440
METHOD FOR PREPARING PRE-HYDROLYZED POLYSILICATE
3y 2m to grant Granted Nov 10, 2026
Patent 12781035
WATER DISPERSION OF VINYL HALIDE COPOLYMER AND FILM
4y 1m to grant Granted Nov 03, 2026
Patent 12781065
RHEOLOGY-MODIFYING TRIURETHANE COMPOUND
3y 10m to grant Granted Nov 03, 2026
Patent 12781026
FIBROUS CELLULOSE-CONTAINING MATERIAL, FIBROUS CELLULOSE COMPOSITE RESIN, AND METHOD FOR PREPARING FIBROUS CELLULOSE-CONTAINING MATERIAL
3y 2m to grant Granted Nov 03, 2026
Patent 12781033
MOLDED ARTICLE
2y 9m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
72%
Grant Probability
84%
With Interview (+11.9%)
2y 5m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 818 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month